Abstract:Chimeric antigen receptors (CAR) redirect T cells to specifically recognize and eliminate tumor cells. CAR-T therapy has achieved successful clinical outcomes, and it has been transformed into commercially available products to treat acute lymphoblastic leukemia and B cell lymphoma. These breakthroughs have motivated hundreds of CAR-T clinical trials initiated each year, with ≈900 cases registered on the ClinicalTrials website till 2021. Accumulating clinical experiences have highlighted some limitations of this strategy, e.g., relapse after complete response, poor efficacy in solid tumors, on-target off-tumor toxicities, lack of persistence, and tumor resistance. These challenges limit the therapeutic application of CAR-T cells. Multidisciplinary approaches are actively investigated to address these issues. In this review, the antigens, CAR designs, and cell sources are summarized in clinical trials from 2020 to 2021. The innovative modular and programmable designs in CAR-T cells, including advances in signaling domains, antigen-recognition domains, T cell engineering, and cell resources, are further discussed. Integrative genetic and chemical engineering strategies are promising to improve the versatility, antitumor efficacy, persistence, and safety of CAR-T cells. In the future, the next generation of CAR-T cell therapies will offer more options for patients who are refractory to standard tumor therapies.

Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies

Novel Cellular Immunotherapies for Hematological Malignancies: Recent Updates from the 2021 ASH Annual Meeting

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference

Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

[Development of dual-targeted CAR T-cell therapy]

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

Progress on CAR-T Cell Therapy for Hematological Malignancies

CAR-T cell combination therapies in hematologic malignancies

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting